A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Study to Evaluate Clinical Efficacy and Safety of Deucravacitinib (BMS-986165) in Participants With Alopecia Areata
Latest Information Update: 04 Mar 2025
At a glance
- Drugs Deucravacitinib (Primary)
- Indications Alopecia areata
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 29 May 2024 Status changed from active, no longer recruiting to discontinued.
- 20 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 31 Jan 2023 Status changed from not yet recruiting to recruiting.